Hybrigenics (FR)

Hybrigenics SA is a public Paris-based biopharmaceutical group focused on pharmaceutical R&D mainly in oncology, and with a fully-owned subsidiary, Hybrigenics Services SAS, dedicated to providing protein interaction services. Hybrigenics is developing inecalcitol, an oral vitamin D receptor agonist, for prostate cancer. A Phase IIa study has just been completed in castrate-resistant prostate cancer (CRPC) patients in combination with Taxotere®. Hybrigenics’ research is focused on ubiquitin-specific proteases (USPs), a new class of targets involved in regulating protein degradation. Hybrigenics Services can identify, validate or inhibit functional protein interactions, using its Yeast Two-Hybrid (Y2H) platform, for biological researchers in all life-sciences.